RU2016137834A - КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu - Google Patents
КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu Download PDFInfo
- Publication number
- RU2016137834A RU2016137834A RU2016137834A RU2016137834A RU2016137834A RU 2016137834 A RU2016137834 A RU 2016137834A RU 2016137834 A RU2016137834 A RU 2016137834A RU 2016137834 A RU2016137834 A RU 2016137834A RU 2016137834 A RU2016137834 A RU 2016137834A
- Authority
- RU
- Russia
- Prior art keywords
- neu
- her2
- listeria
- cancer
- recombinant
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 20
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims 19
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title claims 19
- 239000000203 mixture Substances 0.000 title claims 5
- 241000186781 Listeria Species 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 201000008968 osteosarcoma Diseases 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 241000282465 Canis Species 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- 108700026244 Open Reading Frames Proteins 0.000 claims 6
- 230000002503 metabolic effect Effects 0.000 claims 6
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 201000007455 central nervous system cancer Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 229940124551 recombinant vaccine Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108010041525 Alanine racemase Proteins 0.000 claims 2
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 2
- 108090000992 Transferases Proteins 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 230000002949 hemolytic effect Effects 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 210000004898 n-terminal fragment Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000001018 virulence Effects 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/189,008 | 2014-02-25 | ||
| US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 | 2014-05-02 | ||
| US201462076411P | 2014-11-06 | 2014-11-06 | |
| US62/076,411 | 2014-11-06 | ||
| PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016137834A true RU2016137834A (ru) | 2018-03-29 |
Family
ID=54009773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016137834A RU2016137834A (ru) | 2014-02-25 | 2015-02-25 | КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3110942A4 (enExample) |
| JP (1) | JP2017507943A (enExample) |
| KR (2) | KR20240038103A (enExample) |
| CN (1) | CN106661538A (enExample) |
| AU (1) | AU2015223136A1 (enExample) |
| BR (1) | BR112016019534A2 (enExample) |
| CA (1) | CA2940646A1 (enExample) |
| IL (1) | IL247436A0 (enExample) |
| MX (1) | MX2016011114A (enExample) |
| RU (1) | RU2016137834A (enExample) |
| SG (1) | SG11201607036XA (enExample) |
| WO (1) | WO2015130810A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| CA2829960A1 (en) | 2011-03-11 | 2012-09-20 | John Rothman | Listeria-based adjuvants |
| BR112014022662A2 (pt) | 2012-03-12 | 2017-10-03 | Advaxis Inc | Inibição da função de célula supressora seguindo tratamento de vacina de listeria |
| CA2947358A1 (en) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
| SG11201607213QA (en) * | 2014-03-05 | 2016-09-29 | Advaxis Inc | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio |
| AU2015250111A1 (en) | 2014-04-24 | 2016-12-08 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| KR20190082850A (ko) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법 |
| JP7284156B2 (ja) | 2017-09-19 | 2023-05-30 | アドバクシス， インコーポレイテッド | 細菌またはＬｉｓｔｅｒｉａ株の凍結乾燥のための組成物および方法 |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| CN121944092B (zh) * | 2026-03-27 | 2026-07-17 | 哈尔滨医科大学 | 源自枯草芽孢杆菌的微生物多肽在制备抗肿瘤疫苗中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en not_active Ceased
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3110942A4 (en) | 2017-08-30 |
| WO2015130810A2 (en) | 2015-09-03 |
| WO2015130810A3 (en) | 2016-01-28 |
| NZ723750A (en) | 2024-02-23 |
| KR20160122829A (ko) | 2016-10-24 |
| CN106661538A (zh) | 2017-05-10 |
| SG11201607036XA (en) | 2016-09-29 |
| KR20240038103A (ko) | 2024-03-22 |
| JP2017507943A (ja) | 2017-03-23 |
| CA2940646A1 (en) | 2015-09-03 |
| BR112016019534A2 (pt) | 2017-10-24 |
| EP3110942A2 (en) | 2017-01-04 |
| AU2015223136A1 (en) | 2016-09-22 |
| IL247436A0 (en) | 2016-11-30 |
| MX2016011114A (es) | 2017-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507943A5 (enExample) | ||
| JP7535489B2 (ja) | 治療用抗癌ネオエピトープワクチン | |
| JP2013526837A5 (enExample) | ||
| JP2016156828A5 (enExample) | ||
| ES2675825T3 (es) | Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2 | |
| JP2021535749A5 (enExample) | ||
| ES2730718T3 (es) | Vacunas contra el VPH | |
| JP2017195888A5 (enExample) | ||
| CN118576699A (zh) | Hbv疫苗 | |
| JP2017513502A5 (enExample) | ||
| JP2014500724A5 (enExample) | ||
| JP2016202185A (ja) | ホモ二量体タンパク質コンストラクト | |
| EA202091251A2 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
| JP2016505635A5 (enExample) | ||
| Soong et al. | Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53 | |
| KR20230004585A (ko) | 개별화된 치료용 항암 백신 | |
| JP6406647B2 (ja) | 細胞性免疫誘導ワクチン | |
| Soong et al. | Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors | |
| Singer et al. | Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform | |
| ES2605020T3 (es) | Composición de ADN para inducir una respuesta inmunitaria contra macrófagos asociados a tumor | |
| US11123422B2 (en) | Immunogenic composition | |
| NZ723750A (en) | Compositions and methods for the treatment of her2/neu over-expressing tumors | |
| Liu et al. | Prediction and identification of B cell epitopes derived from EWS/FLI-l fusion protein of Ewing’s sarcoma | |
| RU2850342C1 (ru) | Индивидуализированная терапевтическая противораковая вакцина | |
| NZ723750B2 (en) | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180226 |